A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly ...

Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Denmark is heading for its worst year of job losses since the Covid pandemic, as sweeping cuts at pharmaceutical giant Novo ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

A 2.3% quarterly jump, according to Statistics Denmark, was powered almost entirely by the pharmaceutical engine dominated by ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs ...

Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically significant reductions in HbA1c with up to 89.1% achieving HbA1c levels below ...

Novo Nordisk (NVO) announced 5,000 job cuts in Denmark last September, putting the Nordic nation to record its worst year for ...

Denmark’s Novo Nordisk saw its shares rise 4% to 298.50 kroner today, after it announced positive headline results from a ...

() -​Novo Nordisk ‌said on Tuesday ‌its experimental obesity drug, ⁠amycretin,‌ showed statistically significant ‍weight loss ...

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...